## Zamaneh Kassiri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6872600/publications.pdf

Version: 2024-02-01

105 papers 8,345 citations

44069 48 h-index 48315 88 g-index

105 all docs  $\begin{array}{c} 105 \\ \text{docs citations} \end{array}$ 

105 times ranked 10268 citing authors

#	Article	IF	Citations
1	Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis and Tissue Repair, 2012, 5, 15.	3.4	630
2	Angiotensin-Converting Enzyme 2 Suppresses Pathological Hypertrophy, Myocardial Fibrosis, and Cardiac Dysfunction. Circulation, 2010, 122, 717-728.	1.6	383
3	Tumor Necrosis Factor-α Mediates Cardiac Remodeling and Ventricular Dysfunction After Pressure Overload State. Circulation, 2007, 115, 1398-1407.	1.6	335
4	Abnormal TNF activity in Timp3 $\hat{a}$ '/ $\hat{a}$ ' mice leads to chronic hepatic inflammation and failure of liver regeneration. Nature Genetics, 2004, 36, 969-977.	21.4	292
5	Human Recombinant ACE2 Reduces the Progression of Diabetic Nephropathy. Diabetes, 2010, 59, 529-538.	0.6	264
6	Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: A positive feedback mechanism in the RAS. Journal of Molecular and Cellular Cardiology, 2014, 66, 167-176.	1.9	263
7	Loss of Angiotensin-Converting Enzyme-2 (Ace2) Accelerates Diabetic Kidney Injury. American Journal of Pathology, 2007, 171, 438-451.	3.8	235
8	Guidelines for measuring cardiac physiology in mice. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 314, H733-H752.	3.2	220
9	Loss of Angiotensin-Converting Enzyme-2 Leads to the Late Development of Angiotensin II-Dependent Glomerulosclerosis. American Journal of Pathology, 2006, 168, 1808-1820.	3.8	214
10	Prevention of Angiotensin Il–Mediated Renal Oxidative Stress, Inflammation, and Fibrosis by Angiotensin-Converting Enzyme 2. Hypertension, 2011, 57, 314-322.	2.7	200
11	Loss of Angiotensin-Converting Enzyme 2 Accelerates Maladaptive Left Ventricular Remodeling in Response to Myocardial Infarction. Circulation: Heart Failure, 2009, 2, 446-455.	3.9	194
12	Loss of Apelin Exacerbates Myocardial Infarction Adverse Remodeling and Ischemiaâ€reperfusion Injury: Therapeutic Potential of Synthetic Apelin Analogues. Journal of the American Heart Association, 2013, 2, e000249.	3.7	171
13	Angiotensin 1–7 Ameliorates Diabetic Cardiomyopathy and Diastolic Dysfunction in <i>db/db</i> Mice by Reducing Lipotoxicity and Inflammation. Circulation: Heart Failure, 2014, 7, 327-339.	3.9	158
14	TIMP-3 Deficiency Leads to Dilated Cardiomyopathy. Circulation, 2004, 110, 2401-2409.	1.6	154
15	Combination of Tumor Necrosis Factor-α Ablation and Matrix Metalloproteinase Inhibition Prevents Heart Failure After Pressure Overload in Tissue Inhibitor of Metalloproteinase-3 Knock-Out Mice. Circulation Research, 2005, 97, 380-390.	4.5	151
16	Loss of Angiotensin-Converting Enzyme-2 Exacerbates Diabetic Cardiovascular Complications and Leads to Systolic and Vascular Dysfunction. Circulation Research, 2012, 110, 1322-1335.	4.5	141
17	TIMP2 Deficiency Accelerates Adverse Post–Myocardial Infarction Remodeling Because of Enhanced MT1-MMP Activity Despite Lack of MMP2 Activation. Circulation Research, 2010, 106, 796-808.	4.5	140
18	Type 1 diabetic cardiomyopathy in the Akita ( <i>Ins2</i> <sup>WT/C96Y</sup> ) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H2096-H2108.	3.2	139

#	Article	lF	Citations
19	Cutting Edge: Tissue Inhibitor of Metalloproteinase 3 Regulates TNF-Dependent Systemic Inflammation. Journal of Immunology, 2006, 176, 721-725.	0.8	138
20	Agonist-Induced Hypertrophy and Diastolic Dysfunction Are Associated With Selective Reduction in Glucose Oxidation. Circulation: Heart Failure, 2012, 5, 493-503.	3.9	136
21	Extracellular matrix, regional heterogeneity of the aorta, and aortic aneurysm. Experimental and Molecular Medicine, 2019, 51, 1-15.	7.7	116
22	Loss of TIMP3 Enhances Interstitial Nephritis and Fibrosis. Journal of the American Society of Nephrology: JASN, 2009, 20, 1223-1235.	6.1	112
23	Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Failure Reviews, 2012, 17, 693-706.	3.9	111
24	Individual Timp Deficiencies Differentially Impact Pro-MMP-2 Activation. Journal of Biological Chemistry, 2006, 281, 10337-10346.	3.4	108
25	Tissue Inhibitor of Matrix Metalloproteinase-1 Promotes Myocardial Fibrosis by Mediating CD63â $\in$ Integrin $\hat{l}^21$ Interaction. Hypertension, 2017, 69, 1092-1103.	2.7	108
26	Tumor necrosis factor induces matrix metalloproteinases in cardiomyocytes and cardiofibroblasts differentially via superoxide production in a $PI3K\hat{I}^3$ -dependent manner. American Journal of Physiology - Cell Physiology, 2010, 298, C679-C692.	4.6	98
27	Differential role of TIMP2 and TIMP3 in cardiac hypertrophy, fibrosis, and diastolic dysfunction. Cardiovascular Research, 2014, 103, 268-280.	3.8	98
28	Circulating Levels of Tumor Necrosis Factor-Alpha Receptor 2 Are Increased in Heart Failure with Preserved Ejection Fraction Relative to Heart Failure with Reduced Ejection Fraction: Evidence for a Divergence in Pathophysiology. PLoS ONE, 2014, 9, e99495.	2.5	94
29	Extracellular Matrix Communication and Turnover in Cardiac Physiology and Pathology. , 2015, 5, 687-719.		93
30	MMP-2 Mediates Angiotensin II–Induced Hypertension Under the Transcriptional Control of MMP-7 and TACE. Hypertension, 2011, 57, 123-130.	2.7	91
31	Lack of Tissue Inhibitor of Metalloproteinases 2 Leads to Exacerbated Left Ventricular Dysfunction and Adverse Extracellular Matrix Remodeling in Response to Biomechanical Stress. Circulation, 2011, 124, 2094-2105.	1.6	90
32	Tumor Necrosis Factor-α–Converting Enzyme Is a Key Regulator of Agonist-Induced Cardiac Hypertrophy and Fibrosis. Hypertension, 2009, 54, 575-582.	2.7	86
33	Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy. Scientific Reports, 2015, 5, 18132.	3.3	85
34	Divergent Roles of Matrix Metalloproteinase 2 in Pathogenesis of Thoracic Aortic Aneurysm. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 888-898.	2.4	84
35	Simultaneous Transforming Growth Factor $\hat{l}^2$ -Tumor Necrosis Factor Activation and Cross-talk Cause Aberrant Remodeling Response and Myocardial Fibrosis in Timp3-deficient Heart. Journal of Biological Chemistry, 2009, 284, 29893-29904.	3.4	82
36	Angiotensin-Converting Enzyme 2 Is a Critical Determinant of Angiotensin II–Induced Loss of Vascular Smooth Muscle Cells and Adverse Vascular Remodeling. Hypertension, 2014, 64, 157-164.	2.7	81

3

#	Article	IF	CITATIONS
37	Mice with Tissue Inhibitor of Metalloproteinases 4 (Timp4) Deletion Succumb to Induced Myocardial Infarction but Not to Cardiac Pressure Overload. Journal of Biological Chemistry, 2010, 285, 24487-24493.	3.4	80
38	Biology of Tissue Inhibitor of Metalloproteinase 3 (TIMP3), and Its Therapeutic Implications in Cardiovascular Pathology. Frontiers in Physiology, 2020, 11, 661.	2.8	78
39	Reduction ofItoCauses Hypertrophy in Neonatal Rat Ventricular Myocytes. Circulation Research, 2002, 90, 578-585.	4.5	75
40	Matrix Metalloproteinase-7 and ADAM-12 (a Disintegrin and Metalloproteinase-12) Define a Signaling Axis in Agonist-Induced Hypertension and Cardiac Hypertrophy. Circulation, 2009, 119, 2480-2489.	1.6	73
41	Early activation of matrix metalloproteinases underlies the exacerbated systolic and diastolic dysfunction in mice lacking TIMP3 following myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H1012-H1023.	3.2	73
42	Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors. Thrombosis and Haemostasis, 2005, 93, 212-219.	3.4	68
43	Matrix as an Interstitial Transport System. Circulation Research, 2014, 114, 889-902.	4.5	67
44	Loss of Timp3 Gene Leads to Abdominal Aortic Aneurysm Formation in Response to Angiotensin II. Journal of Biological Chemistry, 2012, 287, 44083-44096.	3.4	62
45	TIMP3 is the primary TIMP to regulate agonist-induced vascular remodelling and hypertension. Cardiovascular Research, 2013, 98, 360-371.	3.8	58
46	Guidelines for in vivo mouse models of myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 321, H1056-H1073.	3.2	53
47	TIMP2 and TIMP3 have divergent roles in early renal tubulointerstitial injury. Kidney International, 2014, 85, 82-93.	5.2	52
48	PI3Kα-regulated gelsolin activity is a critical determinant of cardiac cytoskeletal remodeling and heart disease. Nature Communications, 2018, 9, 5390.	12.8	52
49	Loss of p47 <sup>phox</sup> Subunit Enhances Susceptibility to Biomechanical Stress and Heart Failure Because of Dysregulation of Cortactin and Actin Filaments. Circulation Research, 2013, 112, 1542-1556.	4.5	51
50	ADAMs family and relatives in cardiovascular physiology and pathology. Journal of Molecular and Cellular Cardiology, 2016, 93, 186-199.	1.9	51
51	Cell-Specific Functions of ADAM17 Regulate the Progression of Thoracic Aortic Aneurysm. Circulation Research, 2018, 123, 372-388.	4.5	51
52	Loss of PI3KÎ <sup>3</sup> Enhances cAMP-Dependent MMP Remodeling of the Myocardial N-Cadherin Adhesion Complexes and Extracellular Matrix in Response to Early Biomechanical Stress. Circulation Research, 2010, 107, 1275-1289.	4.5	50
53	Myocardial Recovery From Ischemia–Reperfusion Is Compromised in the Absence of Tissue Inhibitor of Metalloproteinase 4. Circulation: Heart Failure, 2014, 7, 652-662.	3.9	50
54	Crossing Into the Next Frontier of Cardiac Extracellular Matrix Research. Circulation Research, 2016, 119, 1040-1045.	4.5	50

#	Article	IF	Citations
55	Myocardial overexpression of TIMP3 after myocardial infarction exerts beneficial effects by promoting angiogenesis and suppressing early proteolysis. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 313, H224-H236.	3.2	50
56	Dysregulation of ACE (Angiotensin-Converting Enzyme)-2 and Renin-Angiotensin Peptides in SARS-CoV-2 Mediated Mortality and End-Organ Injuries. Hypertension, 2022, 79, 365-378.	2.7	50
57	Reinforcing rigor and reproducibility expectations for use of sex and gender in cardiovascular research. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 321, H819-H824.	3.2	49
58	Apelin directs endothelial cell differentiation and vascular repair following immune-mediated injury. Journal of Clinical Investigation, 2019, 130, 94-107.	8.2	43
59	Vitamin E alleviates non-alcoholic fatty liver disease in phosphatidylethanolamine N-methyltransferase deficient mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 14-25.	3.8	42
60	Loss of TIMP3 selectively exacerbates diabetic nephropathy. American Journal of Physiology - Renal Physiology, 2012, 303, F1341-F1352.	2.7	39
61	Differential impact of mechanical unloading on structural and nonstructural components of the extracellular matrix in advanced human heart failure. Translational Research, 2016, 172, 30-44.	5.0	39
62	Apelin protects against abdominal aortic aneurysm and the therapeutic role of neutral endopeptidase resistant apelin analogs. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 13006-13015.	7.1	39
63	Cardiomyocyte A Disintegrin And Metalloproteinase 17 (ADAM17) Is Essential in Post–Myocardial Infarction Repair by Regulating Angiogenesis. Circulation: Heart Failure, 2015, 8, 970-979.	3.9	38
64	Resveratrol mediates therapeutic hepatic effects in acquired and genetic murine models of ironâ€overload. Liver International, 2016, 36, 246-257.	3.9	38
65	Modulation of Systemic Metabolism by MMPâ€2: From MMPâ€2 Deficiency in Mice to MMPâ€2 Deficiency in Patients. , 2016, 6, 1935-1949.		37
66	A Disintegrin and Metalloprotease-17 Regulates Pressure Overload–Induced Myocardial Hypertrophy and Dysfunction Through Proteolytic Processing of Integrin β1. Hypertension, 2016, 68, 937-948.	2.7	37
67	Pathogenic mechanisms and the potential of drug therapies for aortic aneurysm. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H652-H670.	3.2	37
68	Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine <i>N</i> -methyltransferase-deficient mice. American Journal of Physiology - Renal Physiology, 2016, 310, G526-G538.	3.4	32
69	Loss of smooth muscle cell disintegrin and metalloproteinase 17 transiently suppresses angiotensin II-induced hypertension and end-organ damage. Journal of Molecular and Cellular Cardiology, 2017, 103, 11-21.	1.9	32
70	Matrix Metalloproteinaseâ€⊋ Negatively Regulates Cardiac Secreted Phospholipase A <sub>2</sub> to Modulate Inflammation and Fever. Journal of the American Heart Association, 2015, 4, .	3.7	31
71	ADAM (a Disintegrin and Metalloproteinase) 15 Deficiency Exacerbates Ang II (Angiotensin II)–Induced Aortic Remodeling Leading to Abdominal Aortic Aneurysm. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1918-1934.	2.4	31
72	Identification of a Novel Heart–Liver Axis: Matrix Metalloproteinaseâ€⊋ Negatively Regulates Cardiac Secreted Phospholipase A <sub>2</sub> to Modulate Lipid Metabolism and Inflammation in the Liver. Journal of the American Heart Association, 2015, 4, .	3.7	29

#	Article	IF	CITATIONS
73	Females Are Protected From Ironâ€Overload Cardiomyopathy Independent of Iron Metabolism: Key Role of Oxidative Stress. Journal of the American Heart Association, 2017, 6, .	3.7	29
74	Reperfused vs. nonreperfused myocardial infarction: when to use which model. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 321, H208-H213.	3.2	29
75	Sex- and age-specific regulation of ACE2: Insights into severe COVID-19 susceptibility. Journal of Molecular and Cellular Cardiology, 2022, 164, 13-16.	1.9	28
76	Inhibition of Soluble Epoxide Hydrolase Limits Mitochondrial Damage and Preserves Function Following Ischemic Injury. Frontiers in Pharmacology, 2016, 7, 133.	3.5	27
77	Absence of Tissue Inhibitor of Metalloproteinase-4 (TIMP4) ameliorates high fat diet-induced obesity in mice due to defective lipid absorption. Scientific Reports, 2017, 7, 6210.	3.3	27
78	Disparate Remodeling of the Extracellular Matrix and Proteoglycans in Failing Pediatric Versus Adult Hearts. Journal of the American Heart Association, 2018, 7, e010427.	3.7	27
79	The Non-Fibrillar Side of Fibrosis: Contribution of the Basement Membrane, Proteoglycans, and Glycoproteins to Myocardial Fibrosis. Journal of Cardiovascular Development and Disease, 2019, 6, 35.	1.6	25
80	Diverse origins and activation of fibroblasts in cardiac fibrosis. Cellular Signalling, 2021, 78, 109869.	3.6	22
81	Genetic deletion of soluble epoxide hydrolase provides cardioprotective responses following myocardial infarction in aged mice. Prostaglandins and Other Lipid Mediators, 2017, 132, 47-58.	1.9	21
82	Phosphoinositide 3-kinase $\hat{l}^2$ mediates microvascular endothelial repair of thrombotic microangiopathy. Blood, 2014, 124, 2142-2149.	1.4	19
83	Matrix Metalloproteinase-2 Mediates a Mechanism of Metabolic Cardioprotection Consisting of Negative Regulation of the Sterol Regulatory Element–Binding Protein-2/3-Hydroxy-3-Methylglutaryl-CoA Reductase Pathway in the Heart. Hypertension, 2015, 65, 882-888.	2.7	19
84	Novel Role for Matrix Metalloproteinase 9 in Modulation of Cholesterol Metabolism. Journal of the American Heart Association, $2016,5,1$	3.7	19
85	Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine N-methyltransferase. Journal of Lipid Research, 2017, 58, 656-667.	4.2	18
86	TIMP3 deficiency exacerbates iron overload-mediated cardiomyopathy and liver disease. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 314, H978-H990.	3.2	18
87	PI3KÎ $\pm$ is essential for the recovery from Cre/tamoxifen cardiotoxicity and in myocardial insulin signalling but is not required for normal myocardial contractility in the adult heart. Cardiovascular Research, 2015, 105, 292-303.	3.8	16
88	Gender-dependent aortic remodelling in patients with bicuspid aortic valve-associated thoracic aortic aneurysm. Journal of Molecular Medicine, 2014, 92, 939-949.	3.9	14
89	The Human Explanted Heart Program: A translational bridge for cardiovascular medicine. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 165995.	3.8	14
90	Molecular components of transient outward potassium current in cultured neonatal rat ventricular myocytes. Journal of Molecular Medicine, 2002, 80, 351-358.	3.9	13

#	Article	IF	CITATIONS
91	Soluble Epoxide Hydrolase in Aged Female Mice and Human Explanted Hearts Following Ischemic Injury. International Journal of Molecular Sciences, 2021, 22, 1691.	4.1	12
92	Loss of TIMP4 (Tissue Inhibitor of Metalloproteinase 4) Promotes Atherosclerotic Plaque Deposition in the Abdominal Aorta Despite Suppressed Plasma Cholesterol Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1874-1889.	2.4	10
93	Disintegrin and metalloproteinases (ADAMs and ADAM-TSs), the emerging family of proteases in heart physiology and pathology. Current Opinion in Physiology, 2018, 1, 34-45.	1.8	9
94	Pharmacological and cell-specific genetic PI3K $\hat{l}\pm$ inhibition worsens cardiac remodeling after myocardial infarction. Journal of Molecular and Cellular Cardiology, 2021, 157, 17-30.	1.9	9
95	ADAM15 is required for optimal collagen cross-linking and scar formation following myocardial infarction. Matrix Biology, 2022, 105, 127-143.	3.6	9
96	Transcriptomic Bioinformatic Analyses of Atria Uncover Involvement of Pathways Related to Strain and Post-translational Modification of Collagen in Increased Atrial Fibrillation Vulnerability in Intensely Exercised Mice. Frontiers in Physiology, 2020, 11, 605671.	2.8	8
97	Gelsolin is an important mediator of Angiotensin IIâ€induced activation of cardiac fibroblasts and fibrosis. FASEB Journal, 2021, 35, e21932.	0.5	8
98	Modulation of Cardiac Fibrosis in and Beyond Cells. Frontiers in Molecular Biosciences, 2021, 8, 750626.	3.5	5
99	We are the change we seek. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 320, H1411-H1414.	3.2	4
100	Disintegrin and Metalloproteinases (ADAMs [A Disintegrin and Metalloproteinase] and ADAMTSs) Tj ETQq0 0 0 rg	gBT /Over 2.7	ock 10 Tf 50
101	Function of $TGF\hat{l}^2$ (Transforming Growth Factor- $\hat{l}^2$ ) Receptor in the Vein Is Not in Vain. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 884-885.	2.4	1
102	ANGIOTENSIN II-MEDIATED MYOCARDIAL EXPRESSION OF MMP2, MMP9 AND MT1-MMP WERE ENHANCED IN ACE2-NULL MICE. Heart, 2012, 98, E9.2-E9.	2.9	0
103	LOXury of inhibiting fibrosis in volume overload cardiomyopathy. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 315, H629-H631.	3.2	0
104	Tissue Inhibitor of Matrix Metalloproteinases in the Pathogenesis of Heart Failure Syndromes. , $2013$ , , $445-465$ .		0
105	Remodelling of the Cardiac Extracellular Matrix: Role of Collagen Degradation and Accumulation in Pathogenesis of Heart Failure. , 2015, , 219-235.		0